Patients with a certain B-cell malignancy and abnormal liver function tests at diagnosis are at risk of shorter overall survival compared with those who have normal liver function. READ MORE
Oral ibrutinib is a better bet than intravenous temsirolimus in previously treated mantle-cell lymphoma.
Research in Review
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to a study published in the Journal of Clinical Oncology.
Patients with chronic myeloid leukemia and a history of prior malignancies appear to have the same outcomes as patients with no prior malignancies, according to a study published in Cancer.
Researchers may have found a cost-efficient way of examining individual leukemia cells, which could transform treatment strategies and make care more personalized.